Abstract:
Cyclo-L-glycyl-L-2-Allylproline (NNZ 2591) , a modified diketppiperazine, is neuroprotective and improves long-term function after hypoxic-ischemic brain injury in rats. The present studies reveal that early treatment with NNZ 2591 protects against the motor deficit induced by 6-OHDA and the tretment initiated after the establishment of motor impairment siginificantly improves long-term motor function. These effects of NNZ 2591 on functional recovery were independent of dopamine depletion and also appeared not to be symptomatic as the improved motor function was long -lasting. NNZ 2591 has potential as a therapeutic agent for neurodegeneratiive disorders
